Using Post-bronchodilator FEV1 is Better Than Pre-bronchodilator FEV1 in Evaluation of COPD Severity

Abstract Background: The current standards for the diagnosis and treatment of patients with COPD clearly rely on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria based on post-bronchodilator spirometric values. However, clinical evidence for using the post-bronchodilator FEV1 in the severity classification has not been fully investigated. Methods: Patients with COPD were enrolled and followed up prospectively between October 2006 and January 2011. We compared the observed 3-year risk of all causes and respiratory mortality with the risk predicted by the pre- and post-bronchodilator percent predicted FEV1. Other important phenotypes including BMI, MMRC dyspnea scale, ECOG performance status and severe AECOPD (acute exacerbation) were also compared between the two groups. The different severity classifications of COPD, measured according the GOLD guidelines by post- and pre-bronchodilator percent predicted FEV1 were compared for prediction of mortality. Results: There were 35 deaths among the 300 COPD patients (11.7%). Multivariate analysis showed that the post-bronchodilator percent predicted FEV1 was a significant independent predictor of mortality but pre-bronchodilator percent predicted FEV1 was not (p = 0.008 vs 0.126) and it was more strongly correlated with all studied predictors of outcome than the pre-bronchodilator percent predicted FEV1. Kaplan-Meier analysis showed that the discrimination ability to predict mortality from the GOLD criteria using post bronchodilator percent predicted FEV1 (p = 0.009) was better than using pre-bronchodilator percent predicted FEV1 (p = 0.131). Conclusions: The post-bronchodilator percent predicted FEV1 is better than the pre-bronchodilator percent predicted FEV1 in the evaluation of the severity of disease in COPD patients and is more accurate in predicting the risk of death by the GOLD classification.

[1]  F Neukirch,et al.  An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages , 2004, Thorax.

[2]  E. Wouters,et al.  Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. , 1993, The American review of respiratory disease.

[3]  P. Sterk Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 , 2004, European Respiratory Journal.

[4]  W. Kannel,et al.  PULMONARY FUNCTION: RELATION TO AGING, CIGARETTE HABIT, AND MORTALITY , 1976 .

[5]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[6]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[7]  J. Wilson,et al.  Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. , 1999, Chest.

[8]  J. Soriano,et al.  Recent improvement in long-term survival after a COPD hospitalisation , 2010, Thorax.

[9]  A. Gulsvik,et al.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.

[10]  Ulrike Held,et al.  Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.

[11]  M. Niederman,et al.  Acute exacerbation of COPD: factors associated with poor treatment outcome. , 2000, Chest.

[12]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[13]  D. Mannino,et al.  Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. , 2008, Archives of internal medicine.

[14]  P. Calverley,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[15]  M. Ferrer,et al.  Chronic Obstructive Pulmonary Disease Stage and Health-Related Quality of Life , 1997, Annals of Internal Medicine.

[16]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[17]  A. Buist,et al.  Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers , 2002, European Respiratory Journal.

[18]  M. Pearson,et al.  Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease , 2002, Thorax.

[19]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[20]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[21]  T. Hsiue,et al.  Small airways obstruction syndrome in clinical practice , 2009, Respirology.

[22]  Jordi Alonso,et al.  Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[23]  H. Kerstjens The GOLD classification has not advanced understanding of COPD. , 2004, American journal of respiratory and critical care medicine.

[24]  M. Tsukino,et al.  Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. , 2003, American journal of respiratory and critical care medicine.

[25]  G H Guyatt,et al.  Long-term effects of outpatient rehabilitation of COPD: A randomized trial. , 2000, Chest.

[26]  Liam Ck A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .